Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders

Frontiers in Cellular Neuroscience

Volumn 8, Issue JULY, 2014, Pages

  Irwin, Ronald W ^a   Solinsky, Christine M ^a   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Allopregnanolone; Alzheimer's disease; Cholesterol homeostasis; Myelin; Neurogenesis; Regeneration; Treatment regimen; amyloid

Indexed keywords

EID: 84905182320     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00203     Document Type: Review

References (160)

1. Abramian, A. M., Comenencia-Ortiz, E., Modgil, A., Vien, T. N., Nakamura, Y., Moore, Y. E., et al. (2014). Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors. Proc. Natl. Acad. Sci. U S A.111, 7132-7137. doi: 10.1073/pnas.1403285111
2. Adeosun, S. O., Hou, X., Jiao, Y., Zheng, B., Henry, S., Hill, R., et al. (2012). Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One.7:e50040. doi: 10.1371/journal.pone.0050040
3. Afrazi, S., Esmaeili-Mahani, S., Sheibani, V., and Abbasnejad, M. (2014). Neurosteroid allopregnanolone attenuates high glucose-induced apoptosis and prevents experimental diabetic neuropathic pain: in vitro and in vivo studies.J. Steroid Biochem. Mol. Biol.139, 98-103. doi: 10.1016/j.jsbmb.2013.10.010
4. Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement.7, 270-279. doi: 10.1016/j.jalz.2011.03.008
5. Annegers, J. F., Hauser, W. A., Coan, S. P., and Rocca, W. A. (1998). A population-based study of seizures after traumatic brain injuries. N. Engl. J. Med.338, 20-24. doi: 10.1056/nejm199801013380104
6. Becker, R. E., Greig, N. H., Giacobini, E., Schneider, L. S., and Ferrucci, L. (2014). A new roadmap for drug development for Alzheimer's disease. Nat. Rev. Drug Discov.13:156. doi: 10.1038/nrd3842-c2
7. Belelli, D., and Lambert, J. J. (2005). Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci.6, 565-575. doi: 10.1038/nrn1703
8. Benarroch, E. E. (2007). Neurosteroids: endogenous modulators of neuronal excitability and plasticity. Neurology.8, 945-947. doi: 10.1212/01.wnl.0000257836.09570.e1
9. Bengtsson, S. K., Johansson, M., Backstrom, T., and Wang, M. (2012). Chronic allopregnanolone treatment accelerates Alzheimer's disease development in AbetaPP(Swe)PSEN1(DeltaE9) mice. J. Alzheimers Dis.31, 71-84. doi: 10.3233/JAD-2012-120268
10. Bengtsson, S. K., Johansson, M., Backstrom, T., Nitsch, R. M., and Wang, M. (2013). Brief but chronic increase in allopregnanolone cause accelerated AD pathology differently in two mouse models. Curr. Alzheimer Res.10, 38-47. doi: 10.2174/1567205011310010006
11. Bernardi, F., Lanzone, A., Cento, R. M., Spada, R. S., Pezzani, I., Genazzani, A. D., et al. (2000). Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur. J. Endocrinol.142, 466-471. doi: 10.1530/eje.0.1420466
12. Bixo, M., Andersson, A., Winblad, B., Purdy, R. H., and Backstrom, T. (1997). Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res.764, 173-178. doi: 10.1016/s0006-8993(97)00455-1
13. Brinton, R. D. (1994). The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces cytoarchitectural regression in cultured fetal hippocampal neurons. J. Neurosci.14, 2763-2774.
14. Brinton, R. D. (2013). Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat. Rev. Endocrinol.9, 241-250. doi: 10.1038/nrendo.2013.31
15. Brinton, R. D., and Wang, J. M. (2006). Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res., 11-17. doi: 10.2174/156720506775697160
16. Cao, Z., Hulsizer, S., Tassone, F., Tang, H. T., Hagerman, R. J., Rogawski, M. A., et al. (2012). Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum. Mol. Genet.21, 2923-2935. doi: 10.1093/hmg/dds118
17. Carmichael, S. T. (2010). Translating the frontiers of brain repair to treatments: starting not to break the rules. Neurobiol. Dis.37, 237-242. doi: 10.1016/j.nbd.2009.09.005
18. Chapell, R., Bueno, O. F., Alvarez-Hernandez, X., Robinson, L. C., and Leidenheimer, N. J. (1998). Activation of protein kinase C induces gamma-aminobutyric acid type A receptor internalization in Xenopus oocytes. J. Biol. Chem.273, 32595-32601. doi: 10.1074/jbc.273.49.32595
19. Chen, S., Wang, J. M., Irwin, R. W., Yao, J., Liu, L., and Brinton, R. D. (2011). Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of alzheimer's disease. PLoS One.6:e24293. doi: 10.1371/journal.pone.0024293
20. Crowley, S. K., and Girdler, S. S. (2014). Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology (Berl). doi: 10.1007/s00213-014-3572-8. [Epub ahead of print].
21. Damianisch, K., Rupprecht, R., and Lancel, M. (2001). The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology.25, 576-584. doi: 10.1016/s0893-133x(01)00242-1
22. Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., et al. (2012). A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron.76, 908-920. doi: 10.1016/j.neuron.2012.10.029
23. di Michele, F., Longone, P., Romeo, E., Lucchetti, S., Brusa, L., Pierantozzi, M., et al. (2003). Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol. Sci.24, 172-173. doi: 10.1007/s10072-003-0115-1
24. di Michele, F., Luchetti, S., Bernardi, G., Romeo, E., and Longone, P. (2013). Neurosteroid and neurotransmitter alterations in Parkinson's disease. Front. Neuroendocrinol.34, 132-142. doi: 10.1016/j.yfrne.2013.03.001
25. Dieriks, B. V., Waldvogel, H. J., Monzo, H. J., Faull, R. L., and Curtis, M. A. (2013). GABA(A) receptor characterization and subunit localization in the human sub ventricular zone. J. Chem. Neuroanat.52, 58-68. doi: 10.1016/j.jchemneu.2013.06.001
26. Djebaili, M., Guo, Q., Pettus, E. H., Hoffman, S. W., and Stein, D. G. (2005). The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis and functional deficits after traumatic brain injury in rats. J. Neurotrauma.22, 106-118. doi: 10.1089/neu.2005.22.106
27. Dong, E., Matsumoto, K., Uzunova, V., Sugaya, I., Takahata, H., Nomura, H., et al. (2001). Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. U S A.98, 2849-2854. doi: 10.1073/pnas.051628598
28. Donkin, J. J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., et al. (2010). ATP-binding cassette transporter A1 mediates the beneficial effects of the liver-X-receptor agonist GW3965 on object recognition memory and amyloid burden in APP/PS1 mice. J. Biol. Chem.285, 34144-34154. doi: 10.1074/jbc.m110.108100
29. Ernst, A., Alkass, K., Bernard, S., Salehpour, M., Perl, S., Tisdale, J., et al. (2014). Neurogenesis in the striatum of the adult human brain. Cell.156, 1072-1083. doi: 10.1016/j.cell.2014.01.044
30. Fan, X., Kim, H. J., Bouton, D., Warner, M., and Gustafsson, J. A. (2008). Expression of liver X receptor beta is essential for formation of superficial cortical layers and migration of later-born neurons. Proc. Natl. Acad. Sci. U S A.105, 13445-13450. doi: 10.1073/pnas.0806974105
31. Filippova, N., Sedelnikova, A., Zong, Y., Fortinberry, H., and Weiss, D. S. (2000). Regulation of recombinant gamma-aminobutyric acid (GABA)(A) and GABA(C) receptors by protein kinase C. Mol. Pharmacol.57, 847-856.
32. Food Drug Administration, Center for Drugs Evaluation Research. (2010). Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Maryland: FDA.
33. Food Drug Administration, Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Maryland: FDA.
34. Gage, F. H., and Temple, S. (2013). Neural stem cells: generating and regenerating the brain. Neuron.80, 588-601. doi: 10.1016/j.neuron.2013.10.037
35. Gago, N., El-Etr, M., Sananes, N., Cadepond, F., Samuel, D., Avellana-Adalid, V., et al. (2004). 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J. Neurosci. Res.78, 770-783. doi: 10.1002/jnr.20348
36. Garay, L. I., Gonzalez Deniselle, M. C., Brocca, M. E., Lima, A., Roig, P., and De Nicola, A. F. (2012). Progesterone down-regulates spinal cord inflammatory mediators and increases myelination in experimental autoimmune encephalomyelitis. Neuroscience.226, 40-50. doi: 10.1016/j.neuroscience.2012.09.032
37. Gasior, M., Ungard, J. T., Beekman, M., Carter, R. B., and Witkin, J. M. (2000). Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology.39, 1184-1196. doi: 10.1016/s0028-3908(99)00190-2
38. Gee, K. W., Bolger, M. B., Brinton, R. E., Coirini, H., and Mcewen, B. S. (1988). Steroid modulation of the chloride ionophore in rat brain: structure-activity requirements, regional dependence and mechanism of action. J. Pharmacol. Exp. Ther.246, 803-812.
39. Gee, K. W., Chang, W. C., Brinton, R. E., and Mcewen, B. S. (1987). GABA-dependent modulation of the Cl-ionophore by steroids in rat brain. Eur. J. Pharmacol.136, 419-423. doi: 10.1016/0014-2999(87)90317-7
40. Genazzani, A. R., Bernardi, F., Stomati, M., Monteleone, P., Luisi, S., Rubino, S., et al. (2000). Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology.72, 162-170. doi: 10.1159/000054583
41. Genazzani, A. R., Petraglia, F., Bernardi, F., Casarosa, E., Salvestroni, C., Tonetti, A., et al. (1998). Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J. Clin. Endocrinol. Metab.83, 2099-2103. doi: 10.1210/jc.83.6.2099
42. Ghoumari, A. M., Ibanez, C., El-Etr, M., Leclerc, P., Eychenne, B., O'malley, B. W., et al. (2003). Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem.86, 848-859. doi: 10.1046/j.1471-4159.2003.01881.x
43. Gillies, G. E., and Mcarthur, S. (2010). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev.62, 155-198. doi: 10.1124/pr.109.002071
44. Goodkin, H. P., Yeh, J. L., and Kapur, J. (2005). Status epilepticus increases the intracellular accumulation of GABAA receptors. J. Neurosci.25, 5511-5520. doi: 10.1523/jneurosci.0900-05.2005
45. Grant, K. A., Helms, C. M., Rogers, L. S., and Purdy, R. H. (2008). Neuroactive steroid stereospecificity of ethanol-like discriminative stimulus effects in monkeys. J. Pharmacol. Exp. Ther.326, 354-361. doi: 10.1124/jpet.108.137315
46. Griffin, L. D., and Mellon, S. H. (2001). Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release. Endocrinology.142, 4617-4622. doi: 10.1210/en.142.11.4617
47. Griffin, L. D., Gong, W., Verot, L., and Mellon, S. H. (2004). Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med.10, 704-711. doi: 10.1038/nm1073
48. Haas, H., and Panula, P. (2003). The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci.4, 121-130. doi: 10.1038/nrn1034
49. Hafner, V., Czock, D., Burhenne, J., Riedel, K. D., Bommer, J., Mikus, G., et al. (2010). Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob. Agents Chemother.54, 2596-2602. doi: 10.1128/aac.01540-09
50. He, J., Evans, C. O., Hoffman, S. W., Oyesiku, N. M., and Stein, D. G. (2004a). Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp. Neurol.189, 404-412. doi: 10.1016/j.expneurol.2004.06.008
51. He, J., Hoffman, S. W., and Stein, D. G. (2004b). Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor. Neurol. Neurosci.22, 19-31.
52. Hosie, A. M., Wilkins, M. E., Da Silva, H. M., and Smart, T. G. (2006). Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature.444, 486-489. doi: 10.1038/nature05324
53. Hutson, C. B., Lazo, C. R., Mortazavi, F., Giza, C. C., Hovda, D., and Chesselet, M. F. (2011). Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J. Neurotrauma.28, 1783-1801. doi: 10.1089/neu.2010.1723
54. Irwin, R. W., and Brinton, R. D. (2014). Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. Prog. Neurobiol.113, 40-55. doi: 10.1016/j.pneurobio.2013.08.004
55. Irwin, R. W., Solinsky, C. M., Chen, S., and Brinton, R. D. (2013). Preclinical safety and efficacy of allopregnanolone for Alzheimer's disease therapy. Soc. Neurosci. Annu. Meet. Abstracts.
56. Irwin, R. W., Wang, J. M., Chen, S., and Brinton, R. D. (2011). Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Front. Endocrinol. (Lausanne).2:117. doi: 10.3389/fendo.2011.00117
57. Jakobsson, T., Treuter, E., Gustafsson, J. A., and Steffensen, K. R. (2012). Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci.33, 394-404. doi: 10.1016/j.tips.2012.03.013
58. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., et al. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron.58, 681-693. doi: 10.1016/j.neuron.2008.04.010
59. Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., et al. (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U S A.101, 343-347. doi: 10.1073/pnas.263479410
60. Johnson, V. E., Stewart, W., and Smith, D. H. (2012). Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol.22, 142-149. doi: 10.1111/j.1750-3639.2011.00513.x
61. Jovanovic, J. N., Thomas, P., Kittler, J. T., Smart, T. G., and Moss, S. J. (2004). Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity and cell-surface stability. J. Neurosci.24, 522-530. doi: 10.1523/jneurosci.3606-03.2004
62. Juptner, M., and Hiemke, C. (1990). Sex differences in GABAA receptor binding in rat brain measured by an improved in vitro binding assay. Exp. Brain Res.81, 297-302. doi: 10.1007/bf00228119
63. Kaminski, R. M., Livingood, M. R., and Rogawski, M. A. (2004). Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia.45, 864-867. doi: 10.1111/j.0013-9580.2004.04504.x
64. Kask, K., Backstrom, T., Lundgren, P., and Sundstrom Poromaa, I. (2009). Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol. Biochem. Behav.92, 608-613. doi: 10.1016/j.pbb.2009.02.014
65. Kask, K., Backstrom, T., Nilsson, L. G., and Sundstrom-Poromaa, I. (2008). Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology (Berl).199, 161-168. doi: 10.1007/s00213-008-1150-7
66. Kelley, M. H., Kuroiwa, M., Taguchi, N., and Herson, P. S. (2011). Sex difference in sensitivity to allopregnanolone neuroprotection in mice correlates with effect on spontaneous inhibitory post synaptic currents. Neuropharmacology.61, 724-729. doi: 10.1016/j.neuropharm.2011.05.017
67. Kerrigan, J. F., Shields, W. D., Nelson, T. Y., Bluestone, D. L., Dodson, W. E., Bourgeois, B. F., et al. (2000). Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res.42, 133-139. doi: 10.1016/s0920-1211(00)00170-4
68. Kittler, J. T., Delmas, P., Jovanovic, J. N., Brown, D. A., Smart, T. G., and Moss, S. J. (2000). Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J. Neurosci.20, 7972-7977.
69. Koldamova, R., Fitz, N. F., and Lefterov, I. (2010). The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim. Biophys. Acta.1801, 824-830. doi: 10.1016/j.bbalip.2010.02.010
70. Lancel, M. (1999). Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep.22, 33-42.
71. Lazarov, O., and Marr, R. A. (2010). Neurogenesis and Alzheimer's disease: at the crossroads. Exp. Neurol.223, 267-281. doi: 10.1016/j.expneurol.2009.08.009
72. Leduc, V., Jasmin-Belanger, S., and Poirier, J. (2010a). APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol. Med.16, 469-477. doi: 10.1016/j.molmed.2010.07.008
73. Leduc, V., Jasmin-Belanger, S., and Poirier, J. (2010b). APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol. Med.16, 469-477. doi: 10.1016/j.molmed.2010.07.008
74. Leonelli, E., Bianchi, R., Cavaletti, G., Caruso, D., Crippa, D., Garcia-Segura, L. M., et al. (2007). Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience.144, 1293-1304. doi: 10.1016/j.neuroscience.2006.11.014
75. Liu, J., Rone, M. B., and Papadopoulos, V. (2006). Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J. Biol. Chem.281, 38879-38893. doi: 10.1074/jbc.M608820200
76. Liu, X., Wang, Q., Haydar, T. F., and Bordey, A. (2005). Nonsynaptic GABA signaling in postnatal subventricular zone controls proliferation of GFAP-expressing progenitors. Nat. Neurosci.8, 1179-1187. doi: 10.1038/nn1522
77. Lo, A. W., Ho, C., Cummings, J., and Kosik, K. S. (2014). Parallel discovery of Alzheimer's therapeutics. Sci. Transl. Med.6:241cm245. doi: 10.1126/scitranslmed.3008228
78. Lovick, T. A. (2008). GABA in the female brain-oestrous cycle-related changes in GABAergic function in the periaqueductal grey matter. Pharmacol. Biochem. Behav.90, 43-50. doi: 10.1016/j.pbb.2007.12.014
79. Luchetti, S., Bossers, K., Frajese, G. V., and Swaab, D. F. (2010). Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol.20, 945-951. doi: 10.1111/j.1750-3639.2010.00396.x
80. Luchetti, S., Huitinga, I., and Swaab, D. F. (2011). Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neuroscience.191, 6-21. doi: 10.1016/j.neuroscience.2011.04.010
81. Luisi, S., Petraglia, F., Benedetto, C., Nappi, R. E., Bernardi, F., Fadalti, M., et al. (2000). Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery and in hypertensive patients. J. Clin. Endocrinol. Metab.85, 2429-2433. doi: 10.1210/jc.85.7.2429
82. Luke, D. R., Tomaszewski, K., Damle, B., and Schlamm, H. T. (2010). Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J. Pharm. Sci.99, 3291-3301. doi: 10.1002/jps.22109
83. MacNevin, C. J., Atif, F., Sayeed, I., Stein, D. G., and Liotta, D. C. (2009). Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury. J. Med. Chem.52, 6012-6023. doi: 10.1021/jm900712n
84. Mahley, R. W. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science.40, 622-630. doi: 10.1126/science.3283935
85. Malberg, J. E., Eisch, A. J., Nestler, E. J., and Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci.20, 9104-9110.
86. Marx, C. E., Trost, W. T., Shampine, L. J., Stevens, R. D., Hulette, C. M., Steffens, D. C., et al. (2006). The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol. Psychiatry.60, 1287-1294. doi: 10.1016/j.biopsych.2006.06.017
87. Mayo, W., Lemaire, V., Malaterre, J., Rodriguez, J. J., Cayre, M., Stewart, M. G., et al. (2005). Pregnenolone sulfate enhances neurogenesis and PSA-NCAM in young and aged hippocampus. Neurobiol. Aging.26, 103-114. doi: 10.1016/j.neurobiolaging.2004.03.013
88. Melcangi, R. C., Froelichsthal, P., Martini, L., and Vescovi, A. L. (1996). Steroid metabolizing enzymes in pluripotential progenitor central nervous system cells: effect of differentiation and maturation. Neuroscience.72, 467-475. doi: 10.1016/0306-4522(95)00522-6
89. Melcangi, R. C., Magnaghi, V., Cavarretta, I., Zucchi, I., Bovolin, P., D'urso, D., et al. (1999). Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J. Neurosci. Res.56, 349-357. doi: 10.1002/(sici)1097-4547(19990515)56:4<349::aid-jnr3>3.3.co;2-8
90. Meldrum, B. S., and Rogawski, M. A. (2007). Molecular targets for antiepileptic drug development. Neurotherapeutics.4, 18-61. doi: 10.1016/j.nurt.2006.11.010
91. Mellon, S. H. (2007). Neurosteroid regulation of central nervous system development. Pharmacol. Ther.116, 107-124. doi: 10.1016/j.pharmthera.2007.04.011
92. Mellon, S. H., Gong, W., and Schonemann, M. D. (2008). Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res. Rev.57, 410-420. doi: 10.1016/j.brainresrev.2007.05.012
93. Mellon, S. H., Griffin, L. D., and Compagnone, N. A. (2001). Biosynthesis and action of neurosteroids. Brain Res. Brain Res. Rev.37, 3-12. doi: 10.1016/s0165-0173(01)00109-6
94. Mellon, S. H., and Vaudry, H. (2001). Biosynthesis of neurosteroids and regulation of their synthesis. Int. Rev. Neurobiol.46, 33-78. doi: 10.1016/s0074-7742(01)46058-2
95. Meyer, L., Venard, C., Schaeffer, V., Patte-Mensah, C., and Mensah-Nyagan, A. G. (2008). The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol. Dis.30, 30-41. doi: 10.1016/j.nbd.2007.12.001
96. Mueller, B. K., Mueller, R., and Schoemaker, H. (2009). Stimulating neuroregeneration as a therapeutic drug approach for traumatic brain injury. Br. J. Pharmacol.157, 675-685. doi: 10.1111/j.1476-5381.2009.00220.x
97. Mullard, A. (2012). Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov.11, 657-660. doi: 10.1038/nrd3842
98. Mullard, A. (2013). 2012 FDA drug approvals. Nat. Rev. Drug Discov.12, 87-90. doi: 10.1038/nrd3946
99. Naylor, J. C., Kilts, J. D., Hulette, C. M., Steffens, D. C., Blazer, D. G., Ervin, J. F., et al. (2010). Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim. Biophys. Acta.1801, 951-959. doi: 10.1016/j.bbalip.2010.05.006
100. Nelson, L. E., Guo, T. Z., Lu, J., Saper, C. B., Franks, N. P., and Maze, M. (2002). The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat. Neurosci.5, 979-984. doi: 10.1038/nn913
101. Noorbakhsh, F., Baker, G. B., and Power, C. (2014). Allopregnanolone and neuroinflammation: a focus on multiple sclerosis. Front. Cell. Neurosci.8:134. doi: 10.3389/fncel.2014.00134
102. Noorbakhsh, F., Ellestad, K. K., Maingat, F., Warren, K. G., Han, M. H., Steinman, L., et al. (2011). Impaired neurosteroid synthesis in multiple sclerosis. Brain.134, 2703-2721. doi: 10.1093/brain/awr200
103. Overstreet Wadiche, L., Bromberg, D. A., Bensen, A. L., and Westbrook, G. L. (2005). GABAergic signaling to newborn neurons in dentate gyrus. J. Neurophysiol.94, 4528-4532. doi: 10.1152/jn.00633.2005
104. Owens, D. F., and Kriegstein, A. R. (2002). Is there more to GABA than synaptic inhibition? Nat. Rev. Neurosci.3, 715-727. doi: 10.1038/nrn919
105. Palmer, T. D., Schwartz, P. H., Taupin, P., Kaspar, B., Stein, S. A., and Gage, F. H. (2001). Cell culture. Progenitor cells from human brain after death. Nature.411, 42-43. doi: 10.1038/35075141
106. Patte-Mensah, C., Kibaly, C., and Mensah-Nyagan, A. G. (2005). Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. Proc. Natl. Acad. Sci. U S A.102, 9044-9049. doi: 10.1073/pnas.0502968102
107. Paul, S. M., and Purdy, R. H. (1992). Neuroactive steroids. FASEB J.6, 2311-2322.
108. Perry, R. J., Watson, P., and Hodges, J. R. (2000). The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia.38, 252-271. doi: 10.1016/s0028-3932(99)00079-2
109. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., et al. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science.298:1379. doi: 10.1126/science.1078259
110. Pierobon, P., Tino, A., Minei, R., and Marino, G. (2004). Different roles of GABA and glycine in the modulation of chemosensory responses in Hydra vulgaris (Cnidaria, Hydrozoa). Dev. Hydrobiologia.178, 59-66. doi: 10.1007/978-1-4020-2762-8_7
111. Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., et al. (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci.25, 629-636. doi: 10.1523/jneurosci.4337-04.2005
112. Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., et al. (2007). The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci.34, 621-628. doi: 10.1016/j.mcn.2007.01.011
113. Rodriguez, J. J., Jones, V. C., and Verkhratsky, A. (2009). Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model. Neuroreport.20, 907-912. doi: 10.1097/wnr.0b013e32832be77d
114. Rodriguez, J. J., Jones, V. C., Tabuchi, M., Allan, S. M., Knight, E. M., Laferla, F. M., et al. (2008). Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One.3:e2935. doi: 10.1371/journal.pone.0002935
115. Rogawski, M. A., Loya, C. M., Reddy, K., Zolkowska, D., and Lossin, C. (2013). Neuroactive steroids for the treatment of status epilepticus. Epilepsia.54(Suppl. 6), 93-98. doi: 10.1111/epi.12289
116. Rouge-Pont, F., Mayo, W., Marinelli, M., Gingras, M., Le Moal, M., and Piazza, P. V. (2002). The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur. J. Neurosci.16, 169-173. doi: 10.1046/j.1460-9568.2002.02084.x
117. Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., et al. (2010). Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov.9, 971-988. doi: 10.1038/nrd3295
118. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology.73, 2061-2070. doi: 10.1212/wnl.0b013e3181c67808
119. Saredi, S., Patte-Mensah, C., Melcangi, R. C., and Mensah-Nyagan, A. G. (2005). Effect of streptozotocin-induced diabetes on the gene expression and biological activity of 3beta-hydroxysteroid dehydrogenase in the rat spinal cord. Neuroscience.135, 869-877. doi: 10.1016/j.neuroscience.2005.06.033
120. Sayeed, I., Parvez, S., Wali, B., Siemen, D., and Stein, D. G. (2009). Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res.1263, 165-173. doi: 10.1016/j.brainres.2009.01.045
121. Schneider, L. S. (2014). Rethinking the food and drug administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimers Dement.10, 247-250. doi: 10.1016/j.jalz.2013.12.002
122. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., et al. (2000). Role of LXRs in control of lipogenesis. Genes Dev.14, 2831-2838. doi: 10.1101/gad.850400
123. Schumacher, M., Guennoun, R., Robert, F., Carelli, C., Gago, N., Ghoumari, A., et al. (2004). Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm. IGF Res.4(Suppl. A), S18-S33. doi: 10.1016/j.ghir.2004.03.007
124. Schumacher, M., Hussain, R., Gago, N., Oudinet, J. P., Mattern, C., and Ghoumari, A. M. (2012). Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front. Neurosci.6:10. doi: 10.3389/fnins.2012.00010
125. Schumacher, M., Mattern, C., Ghoumari, A., Oudinet, J. P., Liere, P., Labombarda, F., et al. (2014). Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog. Neurobiol.113, 6-39. doi: 10.1016/j.pneurobio.2013.09.004
126. Shenoy, S. D., Spencer, T. A., Mercer-Haines, N. A., Alipour, M., Gargano, M. D., Runge-Morris, M., et al. (2004). CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos.32, 66-71. doi: 10.1124/dmd.32.1.66
127. Singh, C., Liu, L., Wang, J. M., Irwin, R. W., Yao, J., Chen, S., et al. (2012). Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol. Aging.33, 1493-1506. doi: 10.1016/j.neurobiolaging.2011.06.008
128. Sipila, S., Huttu, K., Voipio, J., and Kaila, K. (2004). GABA uptake via GABA transporter-1 modulates GABAergic transmission in the immature hippocampus. J. Neurosci.24, 5877-5880. doi: 10.1523/jneurosci.1287-04.2004
129. Spalding, K. L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H. B., et al. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell.153, 1219-1227. doi: 10.1016/j.cell.2013.05.002
130. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011a). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement.7, 280-292. doi: 10.1016/j.jalz.2011.03.003
131. Sperling, R. A., Jack, C. R. Jr., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., et al. (2011b). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's association research roundtable workgroup. Alzheimers Dement.7, 367-385. doi: 10.1016/j.jalz.2011.05.2351
132. Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., et al. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol.11, 241-249. doi: 10.1016/j.jalz.2012.05.1624
133. Steinmetz, K. L., and Spack, E. G. (2009). The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol.9(Suppl. 1):S2. doi: 10.1186/1471-2377-9-s1-s2
134. Sun, Y., Yao, J., Kim, T. W., and Tall, A. R. (2003). Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem.278, 27688-27694. doi: 10.1074/jbc.m300760200
135. Terwel, D., Steffensen, K. R., Verghese, P. B., Kummer, M. P., Gustafsson, J. A., Holtzman, D. M., et al. (2011). Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis.J. Neurosci.31, 7049-7059. doi: 10.1523/jneurosci.6546-10.2011
136. Timby, E., Balgard, M., Nyberg, S., Spigset, O., Andersson, A., Porankiewicz-Asplund, J., et al. (2006). Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl).186, 414-424. doi: 10.1007/s00213-005-0148-7
137. Turkmen, S., Lofgren, M., Birzniece, V., Backstrom, T., and Johansson, I. M. (2006). Tolerance development to Morris water maze test impairments induced by acute allopregnanolone. Neuroscience.139, 651-659. doi: 10.1016/j.neuroscience.2005.12.031
138. Uzunova, V., Sampson, L., and Uzunov, D. P. (2006). Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl).186, 351-361. doi: 10.1007/s00213-005-0201-6
139. Uzunova, V., Wrynn, A. S., Kinnunen, A., Ceci, M., Kohler, C., and Uzunov, D. P. (2004). Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol.486, 31-34. doi: 10.1016/j.ejphar.2003.12.002
140. van Broekhoven, F., Backstrom, T., Van Luijtelaar, G., Buitelaar, J. K., Smits, P., and Verkes, R. J. (2007). Effects of allopregnanolone on sedation in men and in women on oral contraceptives. Psychoneuroendocrinology.32, 555-564. doi: 10.1016/j.psyneuen.2007.03.009
141. Van Steveninck, A. L., Mandema, J. W., Tuk, B., Van Dijk, J. G., Schoemaker, H. C., Danhof, M., et al. (1993). A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br. J. Clin. Pharmacol.36, 109-115. doi: 10.1111/j.1365-2125.1993.tb04205.x
142. VanLandingham, J. W., Cekic, M., Cutler, S., Hoffman, S. W., and Stein, D. G. (2007). Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci. Lett.425, 94-98. doi: 10.1016/j.neulet.2007.08.045
143. Voss, H. U., Uluc, A. M., Dyke, J. P., Watts, R., Kobylarz, E. J., Mccandliss, B. D., et al. (2006). Possible axonal regrowth in late recovery from the minimally conscious state. J. Clin. Invest.116, 2005-2011. doi: 10.1172/jci27021
144. Wang, J. M., and Brinton, R. D. (2008). Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci.9(Suppl. 2):S11. doi: 10.1186/1471-2202-9-s2-s11
145. Wang, J. M., Irwin, R. W., Liu, L., Chen, S., and Brinton, R. D. (2007). Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr. Alzheimer Res.4, 510-517. doi: 10.2174/156720507783018262
146. Wang, J. M., Johnston, P. B., Ball, B. G., and Brinton, R. D. (2005). The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J. Neurosci.25, 4706-4718. doi: 10.1523/jneurosci.4520-04.2005
147. Wang, J. M., Singh, C., Liu, L., Irwin, R. W., Chen, S., Chung, E. J., et al. (2010). Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A.107, 6498-6503. doi: 10.1073/pnas.1006236107
148. Walker, T. L., Turnbull, G. W., Mackay, E. W., Hannan, A. J., and Bartlett, P. F. (2011). The latent stem cell population is retained in the hippocampus of transgenic Huntington's disease mice but not wild-type mice. PLoS One.6:e18153. doi: 10.1371/journal.pone.0018153
149. Weill-Engerer, S., David, J. P., Sazdovitch, V., Liere, P., Eychenne, B., Pianos, A., et al. (2002). Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J. Clin. Endocrinol. Metab.87, 5138-5143. doi: 10.1210/jc.2002-020878
150. Whitwell, J. L., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, R. C., et al. (2007). 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain.130, 1777-1786. doi: 10.1093/brain/awm112
151. Whitney, K. D., Watson, M. A., Collins, J. L., Benson, W. G., Stone, T. M., Numerick, M. J., et al. (2002). Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol.16, 1378-1385. doi: 10.1210/me.16.6.1378
152. Xiong, H., Callaghan, D., Jones, A., Walker, D. G., Lue, L. F., Beach, T. G., et al. (2008). Cholesterol retention in Alzheimer's brain is responsible for high beta-and gamma-secretase activities and Abeta production. Neurobiol. Dis.29, 422-437. doi: 10.1016/j.nbd.2007.10.005
153. Yang, S. Y., He, X. Y., and Schulz, H. (2005). Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase. Trends Endocrinol. Metab.16, 167-175. doi: 10.1016/j.tem.2005.03.006
154. Yang, Y., Varvel, N. H., Lamb, B. T., and Herrup, K. (2006). Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J. Neurosci.26, 775-784. doi: 10.1523/jneurosci.3707-05.2006
155. Zampieri, S., Mellon, S. H., Butters, T. D., Nevyjel, M., Covey, D. F., Bembi, B., et al. (2009). Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J. Cell. Mol. Med.13, 3786-3796. doi: 10.1111/j.1582-4934.2008.00493.x
156. Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., et al. (2007). Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U S A.104, 10601-10606. doi: 10.1073/pnas.0701096104
157. Zhao, L., Morgan, T. E., Mao, Z., Lin, S., Cadenas, E., Finch, C. E., et al. (2012). Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles. PLoS One.:e31267. doi: 10.1371/journal.pone.0031267
158. Zhu, D., Wang, M. D., Backstrom, T., and Wahlstrom, G. (2001). Evaluation and comparison of the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in the male rat. Br. J. Anaesth.86, 403-412. doi: 10.1093/bja/86.3.403
159. Zolkowska, D., Dhir, A., Cooke, G. R., Wu, C., Zhu, L., Wulff, H., et al. (2013). Anticonvulsant activity of intravenous and intramuscular allopregnenalone. Epilepsy Curr.13(Suppl. 1), 11 (Abst 1.023).
160. Zuccato, C., Valenza, M., and Cattaneo, E. (2010). Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev.90, 905-981. doi: 10.1152/physrev.00041.2009